Skip to main content

Table 3 Competing risk regression analysis of Cambridge Prognostic Groups (CPGs) in the PCBaSe cohort

From: The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study

CPG comparison Sub-hazard ratio 95% confidence interval p value
2 vs. 1 2.30 2.04–2.59 < 0.0001
3 vs. 2 2.11 1.89–2.36 < 0.0001
4 vs. 3 1.56 1.42–1.72 < 0.0001
5 vs. 4 2.72 2.58–2.88 < 0.0001